Corroborating these findings, high expression levels of GPER correlate with poor outcome in premenopausal BC patients in terms of overall survival (OS), progression-free survival (PFS), local relapse-free survival (LRFS) and distant disease-free survival (DDFS) [7]. This evidence concerns the gene GPER1 and breast cancer.